BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
基本信息
- 批准号:10337062
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-10-01 至 2025-09-30
- 项目状态:未结题
- 来源:
- 关键词:AcromegalyAdipose tissueAdultAgeAnimalsAnterior Pituitary GlandAreaAryl Hydrocarbon ReceptorAwardBiochemicalBirthBook ChaptersCardiovascular DiseasesCellsChicagoCitric Acid CycleClinicalClinical ResearchClosure by clampCollaborationsComplement Factor HCuesDataDevelopmentDiabetes MellitusDietDietary Fatty AcidDiseaseDisease ProgressionDoctor of PhilosophyDopamine ReceptorDrug TargetingEndocrinologyEnterobacteria phage P1 Cre recombinaseEnzymesEstrogen ReceptorsEtiologyFacultyFastingFatty AcidsFatty LiverFatty acid glycerol estersFeedbackFibrosisFoundationsFundingFutureGene ExpressionGene ProteinsGeneral PopulationGenesGlucose ClampGlycolysisGrant ReviewGrowthGrowth Hormone ReceptorGrowth Hormone Secreting Pituitary NeoplasmGrowth Hormone Signaling PathwayGuanine + Cytosine CompositionHealthHepaticHepatocyteHormone secretionHumanHydrocarbonsHyperglycemiaHyperinsulinismHypothalamic structureIllinoisImpairmentInflammationInjuryInsulinInsulin ReceptorInsulin ResistanceInsulin-Like Growth Factor IInsulin-Like-Growth Factor I ReceptorInternetInvestigationJAK2 geneJournalsKnock-outLaboratoriesLactationLeadershipLipolysisLiverMalignant neoplasm of liverManuscriptsMass FragmentographyMediatingMedical centerMedicineMetabolicMetabolic DiseasesMetabolismModelingMolecularMusMutationNeuroendocrinologyNon obeseNon-Insulin-Dependent Diabetes MellitusObesityPathway interactionsPatientsPatternPeer ReviewPhysiologyPituitary GlandPituitary HormonesPlasmaProductionProteinsPubertyPublishingReceptor SignalingReportingReproductionResearchResearch PersonnelRiskRoleScienceScientistSeminalServicesSeveritiesSignal PathwaySignal TransductionSocietiesSolidSomatostatin ReceptorSomatotrope CellSomatotrophin increasedSomatotropinSpeedThyroxine-Binding GlobulinTimeTissuesToxic Environmental SubstancesTracerUnited States National Institutes of HealthUniversitiesVeteransWeight GainWorkadeno-associated viral vectorbasecareercombat veterancomorbiditydelivery vehiclediabeticdiabetic patientdiabetic wound healingeditorialexperimental studyextracellularglucose productiongrowth hormone deficiencyhormonal signalshormone resistanceimprovedinjury and repairinsulin sensitivityleptin receptorlipid biosynthesisliver injuryliver transplantationmeetingsmembermetabolic phenotypemilitary veteranmouse modelnon-alcoholic fatty liver diseasenonalcoholic steatohepatitisobese patientspost-doctoral trainingpreventpromoterprotective effectprotein expressionreceptorreconstitutionrepairedrepositorystable isotopetherapy developmenttissue injurytooltransgene deliverytreatment responsetreatment strategytumortumor progressionvibrationwound healing
项目摘要
The overarching theme of my current research is to understand how growth hormone (GH) and insulin-like
growth factor I (IGF1) regulate adult metabolic function and how dysregulation of GH/IGF1 production and
signaling contributes to the progression of metabolic disease, as well as related tissue injury and repair. A major
focus of my work is to understand the etiology of non-alcoholic fatty liver disease (NAFLD). NAFLD represents
a spectrum of excess fat accumulation in the liver (steatosis) without or with inflammation/fibrosis (non-alcoholic
steatohepatitis - NASH). NAFLD is commonly observed in obesity and type 2 diabetes, but is also observed in
non-obese patients associated with cardiovascular disease, where all diseases are more prevalent in Veterans,
compared to the general population. NASH increases the risk of developing liver cancer, and is now recognized
as the leading cause for liver transplantation. Dietary fatty acids (FA) and FA derived from adipose tissue
lipolysis, due to systemic insulin resistance, are major contributors to NAFLD. In addition, enhanced hepatic de
novo lipogenesis (DNL) contributes to NAFLD. Clinical and experimental studies show NAFLD is associated with
reduced GH-signaling (reflected by low plasma GH and hepatic GH resistance, leading to low IGF1 levels). The
reduction in GH-signaling may exacerbate NAFLD, based on studies showing SNPs within the GH / GH receptor
(GHR) /JAK2 / Stat5 signaling pathway are associated with NAFLD. Also, increasing GH can reduce NAFLD in
both humans and mice.
We have reported that adult-onset loss of hepatocyte GH signaling (aHepGHRkd; GHRfl/fl mice treated with an
adeno-associated viral vector expressing thyroxine binding globulin promoter driven Cre [AAV8-TBGp-Cre]) led
to the rapid development of steatosis, associated with an increase in DNL (Cordoba-Chacon et al., Diabetes
2015). Of translational relevance, hepatic DNL/steatosis after aHepGHRkd is sustained with age and associated
with hepatocyte ballooning, inflammation and fibrosis (hallmarks of NASH; Cordoba-Chacon et al.,
Endocrinology 2018). Studies outlined in my current R01 take a multi-level approach to define the
biochemical/molecular mechanisms by which hepatocyte GH-signaling directly controls glycolysis-driven DNL
and steatosis, by manipulating hepatocyte GH signaling in mice by hepatocyte-specific, AAV-vector delivery of
transgenes within the GH-signaling pathway then assessing; gene and protein expression of enzymes in
glycolytic and lipogenic pathways, fatty acid composition by GC/MS, glycolytic flux and TCA cycle intermediates
under hyperinsulinemic:hyperglycemic clamps, using stable isotope tracers. Studies outlined in my current
BL&RD VA Merit are focused how the reduction in hepatocyte GH signaling contributes to diet-induced NASH
and how reconstitution of the GHR signaling pathway (specifically Stat5b activity and/or IGF1 using AAV vector
delivery) may prevent and/or reverse steatosis and liver injury. To date we have exciting preliminary data
suggesting, hepatocyte GH-signaling works independently of Stat5b/IGF1 to suppress hepatic DNL, while Stat5b
is critical to protect the liver from diet-induced injury. These protective effects may extend to other types of liver
injury including those induced by environmental toxins (focus of CACHET pilot award).
In addition to assessing the role of GH/IGF1 in protecting the liver from injury, in collaboration with Timothy
Koh, PhD (UIC, wound healing expert) we are exploring the role of IGF1 in regulating diabetic wound healing.
These studies are funded by a RR&D VA Merit and examine the basic mechanisms of wound healing in mouse
models of insulin-resistance (diet-induced) and diabetes (db/db) with or without hepatic IGF1 production. Studies
will also examine if low-intensity vibration patches (developed and optimized by Onur Bilgen PhD, Rutgers) can
speed wound healing via enhanced IGF1 production/actions. Taken together, these basic studies will help to
identify unique targets that can be used to develop treatment strategies, in order to prevent the deleterious
consequences of obesity/diabetes, which are commonly found in the Veteran population.
我目前研究的首要主题是了解生长激素(GH)和胰岛素样
生长因子I(IGF1)调节成人代谢功能,以及GH/IGF1产生和
信号传导有助于代谢疾病的进展以及相关的组织损伤和修复。一个主要
我的工作重点是了解非酒精性脂肪性肝病(NAFLD)的病因。NAFLD代表
肝脏中一系列过量脂肪积聚(脂肪变性),不伴有或伴有炎症/纤维化(非酒精性
脂肪性肝炎-NASH)。NAFLD通常在肥胖和2型糖尿病中观察到,但也在肥胖和2型糖尿病中观察到。
与心血管疾病相关的非肥胖患者,其中所有疾病在退伍军人中更普遍,
与一般人群相比。NASH增加了患肝癌的风险,现在已经被认识到
是肝移植的主要原因。膳食脂肪酸(FA)和脂肪组织来源的FA
由于全身性胰岛素抵抗引起的脂肪分解是NAFLD的主要原因。此外,增强的肝硬化
新生脂肪生成(DNL)导致NAFLD。临床和实验研究表明,NAFLD与
GH信号传导减少(反映为低血浆GH和肝GH抵抗,导致低IGF 1水平)。的
GH信号的减少可能会加剧NAFLD,基于研究显示GH/GH受体内的SNP
(GHR)/JAK2/Stat5信号通路与NAFLD相关。此外,增加GH可以减少NAFLD,
人类和老鼠都是。
我们已经报道了成年期肝细胞GH信号转导的丢失(aHepGHRkd; GHRfl/fl小鼠用一种
表达甲状腺素结合球蛋白启动子驱动的Cre [AAV8-TBGp-Cre]的腺相关病毒载体)
与DNL增加相关的脂肪变性的快速发展(Cordoba-Chacon等,糖尿病
2015年)的报告。翻译相关性,aHepGHRkd后肝DNL/脂肪变性随着年龄的增长而持续,
肝细胞气球样变、炎症和纤维化(NASH的标志; Cordoba-Chacon等人,
Endocrinology 2018)。在我目前的R01中概述的研究采取多层次的方法来定义
肝细胞GH信号直接控制糖酵解驱动的DNL的生化/分子机制
和脂肪变性,通过肝细胞特异性的AAV载体递送来操纵小鼠中的肝细胞GH信号传导,
GH信号通路内的转基因,然后评估;
糖酵解和脂肪生成途径,GC/MS脂肪酸组成,糖酵解通量和TCA循环中间体
在高胰岛素血症下:高血糖钳夹,使用稳定同位素示踪剂。在我目前的研究中,
BL & RD VA Merit专注于肝细胞GH信号传导的减少如何促成饮食诱导的NASH
以及如何使用AAV载体重建GHR信号传导途径(特别是Stat5b活性和/或IGF 1
递送)可以预防和/或逆转脂肪变性和肝损伤。到目前为止,我们有令人兴奋的初步数据,
提示肝细胞GH信号独立于Stat5b/IGF 1抑制肝DNL,而Stat5b/IGF 1抑制肝DNL,
对保护肝脏免受饮食引起的损伤至关重要。这些保护作用可能会扩展到其他类型的肝脏
伤害,包括环境毒素引起的伤害(CACHET试点奖的重点)。
除了评估GH/IGF 1在保护肝脏免受损伤中的作用外,
Koh博士(UIC,伤口愈合专家)我们正在探索IGF 1在调节糖尿病伤口愈合中的作用。
这些研究由RR & D VA Merit资助,并检查了小鼠伤口愈合的基本机制。
胰岛素抵抗(饮食诱导)和糖尿病(db/db)模型,伴或不伴肝IGF 1产生。研究
还将研究低强度振动补丁(由罗格斯大学Onur Bilgen博士开发和优化)是否可以
通过增强IGF1的产生/作用加速伤口愈合。这些基础研究将有助于
确定可用于制定治疗策略的独特靶点,以防止有害的
肥胖/糖尿病的后果,这是常见于退伍军人群体。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rhonda D Kineman其他文献
Rhonda D Kineman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rhonda D Kineman', 18)}}的其他基金
Hormonal control of NASH development and progression
NASH 发生和进展的激素控制
- 批准号:
10454874 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Hormonal control of NASH development and progression
NASH 发生和进展的激素控制
- 批准号:
10265382 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Hormonal control of NASH development and progression
NASH 发生和进展的激素控制
- 批准号:
9906041 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Hormonal control of NASH development and progression
NASH 发生和进展的激素控制
- 批准号:
10588460 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Low-intensity vibration to improve healing of chronic wounds
低强度振动可促进慢性伤口的愈合
- 批准号:
10264788 - 财政年份:2018
- 资助金额:
-- - 项目类别:
Low-intensity vibration to improve healing of chronic wounds
低强度振动可促进慢性伤口的愈合
- 批准号:
10681198 - 财政年份:2018
- 资助金额:
-- - 项目类别:
相似海外基金
Deciphering the role of adipose tissue in common metabolic disease via adipose tissue proteomics
通过脂肪组织蛋白质组学解读脂肪组织在常见代谢疾病中的作用
- 批准号:
MR/Y013891/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
ESTABLISHING THE ROLE OF ADIPOSE TISSUE INFLAMMATION IN THE REGULATION OF MUSCLE MASS IN OLDER PEOPLE
确定脂肪组织炎症在老年人肌肉质量调节中的作用
- 批准号:
BB/Y006542/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
Activation of human brown adipose tissue using food ingredients that enhance the bioavailability of nitric oxide
使用增强一氧化氮生物利用度的食品成分激活人体棕色脂肪组织
- 批准号:
23H03323 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of new lung regeneration therapies by elucidating the lung regeneration mechanism of adipose tissue-derived stem cells
通过阐明脂肪组织干细胞的肺再生机制开发新的肺再生疗法
- 批准号:
23K08293 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
Canadian Alliance of Healthy Hearts and Minds: Dissecting the Pathways Linking Ectopic Adipose Tissue to Cognitive Dysfunction
加拿大健康心灵联盟:剖析异位脂肪组织与认知功能障碍之间的联系途径
- 批准号:
479570 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Operating Grants
Determinants of Longitudinal Progression of Adipose Tissue Inflammation in Individuals at High-Risk for Type 2 Diabetes: Novel Insights from Metabolomic Profiling
2 型糖尿病高危个体脂肪组织炎症纵向进展的决定因素:代谢组学分析的新见解
- 批准号:
488898 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Operating Grants
A study on the role of brown adipose tissue in the development and maintenance of skeletal muscles
棕色脂肪组织在骨骼肌发育和维持中作用的研究
- 批准号:
23K19922 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Research Activity Start-up
A mechanism of lipid accumulation in brown adipose tissue
棕色脂肪组织中脂质积累的机制
- 批准号:
10605981 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Obesity and Childhood Asthma: The Role of Adipose Tissue
肥胖和儿童哮喘:脂肪组织的作用
- 批准号:
10813753 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Estrogen Signaling in the Ventromedial Hypothalamus Modulates Adipose Tissue Metabolic Adaptation
下丘脑腹内侧区的雌激素信号调节脂肪组织代谢适应
- 批准号:
10604611 - 财政年份:2023
- 资助金额:
-- - 项目类别: